Vimarsana
Biggest News Aggregation in the World

Page 9 - Agns News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Agns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Agns Today - Breaking & Trending Today

Genus (LON:GNS) Earns Hold Rating from Peel Hunt - Vimarsana News

Genus (LON:GNS) Earns Hold Rating from Peel Hunt

Genus (LON:GNS – Get Rating)‘s stock had its “hold” rating restated by Peel Hunt in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a GBX 4,500 ($58.64) target price on the stock. Peel Hunt’s target price suggests a potential upside of 70.71% from the stock’s current price. LON GNS opened […]

Genus (LON:GNS) Hits New 12-Month Low at $2,800.00 - Vimarsana News

Genus (LON:GNS) Hits New 12-Month Low at $2,800.00

Genus plc (LON:GNS – Get Rating) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 2,800 ($36.68) and last traded at GBX 2,814 ($36.86), with a volume of 3455 shares. The stock had previously closed at GBX 2,810 ($36.81). Separately, Liberum Capital restated a “buy” […]

In wake of Central Texas tornado, is Laredo prepared? - Vimarsana News

In wake of Central Texas tornado, is Laredo prepared?

This past week, tornadoes touched down and destroyed many homes and businesses in Central...

Genus (LON:GNS) Reaches New 12-Month Low at $2,818.00 - Vimarsana News

Genus (LON:GNS) Reaches New 12-Month Low at $2,818.00

Genus plc (LON:GNS – Get Rating)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 2,818 ($37.10) and last traded at GBX 2,822 ($37.15), with a volume of 29392 shares trading hands. The stock had previously closed at GBX 2,922 ($38.47). Separately, Liberum Capital reaffirmed […]

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts - Vimarsana News

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts  First clinical data demonstrating effectiveness of HGNS to treat CCC patients As previously disclosed, confirms... | March 14, 2022